M&A

Sanofi to acquire Synthorx for $2.5 billion
Marketwatch
Mon, 12/9/19 - 09:27 am
Sanofi
M&A
Synthorx
Alexion shoots down 'proactive' sale demand from activist investor
Fierce Pharma
Fri, 12/6/19 - 10:42 am
Alexion
investors
M&A
Why Sorrento Therapeutics Was Right to Reject Takeover Bids With A 245% Premium
Motley Fool
Thu, 12/5/19 - 11:29 pm
Sorrento Therapeutics
M&A
ZTlido
Lilly puts its cancer future in Loxo's hands
Biopharma Dive
Thu, 12/5/19 - 10:20 am
Eli Lilly
Loxo Oncology
M&A
cancer
R&D
oncology
Gene Therapy M&A Appetite Provides Lift After Audentes Deal
Yahoo/Bloomberg
Wed, 12/4/19 - 10:02 am
gene therapy
Astellas
Audentes Therapeutics
M&A
Novartis
Medicines Company
Is Clovis Oncology Really a Buyout Candidate?
Motley Fool
Tue, 12/3/19 - 10:21 pm
Clovis Oncology
M&A
Rubraca
oncology
Why Novartis's $9.7 Billion Purchase of The Medicines Company Is Bad News for Amgen
Motley Fool
Mon, 12/2/19 - 11:59 pm
Novartis
Medicines Company
M&A
inclisiran
Japan's Astellas to buy Audentes for $3 billion in gene therapy push
Reuters
Mon, 12/2/19 - 11:58 pm
Astellas
M&A
gene therapy
Audentes Therapeutics
Veloxis wins $1.3B buyout deal, and the new owner plans to follow up with new deals
Endpoints
Tue, 11/26/19 - 09:47 am
Asahi Kasei
Veloxis Pharmaceuticals
M&A
organ rejection
Envarsus XR
kidney transplants
Why Novartis Is Buying The Medicines Company For $9.7 Billion
Forbes
Tue, 11/26/19 - 09:44 am
Novartis
Medicines Company
M&A
inclisiran
Amarin for $20B? Novartis' MedCo deal drives fresh buyout rumors for Vascepa's maker
Fierce Pharma
Mon, 11/25/19 - 09:49 pm
Amarin
M&A
Novartis
Medicines Company
Gilead Sciences
Ex-Purdue CEO stands to earn a huge windfall in Novartis' buyout of the Medicines Co
Endpoints
Mon, 11/25/19 - 09:47 pm
Mark Timney
Purdue Pharma
Novartis
Medicines Company
M&A
Novartis buys Medicines Co. in $9.7B bet on cholesterol drug
Biopharma Dive
Sun, 11/24/19 - 11:38 pm
Novartis
The Medicines Company
M&A
BMS investors bet big on 3 newly acquired Celgene drugs for cancer and MS
Fierce Pharma
Sun, 11/24/19 - 11:35 pm
Bristol-Myers Squibb
Celgene
M&A
ozanimod
liso-cel
bb2121
Does Amarin Have a Dark Horse Suitor?
Motley Fool
Sun, 11/24/19 - 11:32 pm
Amarin
Vascepa
M&A
Gilead Sciences
Put on hold music: Roche delays Spark buyout for the 9th — and quite possibly not the last — time
Endpoints
Fri, 11/22/19 - 10:37 am
Roche
M&A
Spark Therapeutics
Having gobbled up Celgene, the Bristol-Myers CEO ducks questions about his key rival
Stat
Fri, 11/22/19 - 10:00 am
Bristol-Myers Squibb
Celgene
Pharma CEOs
Giovanni Caforio
Merck
M&A
AbbVie Shareholders Have a Lot to Look Forward To With Allergan
Motley Fool
Thu, 11/21/19 - 06:28 pm
AbbVie
Allergan
earnings
M&A
Hologic burns its aesthetics unit
EP Vantage
Thu, 11/21/19 - 10:43 am
devices
medical aesthetics
M&A
Hologic
Cynosure
Sanofi weighing options for consumer healthcare unit: sources
Reuters
Thu, 11/21/19 - 10:37 am
Sanofi
consumer healthcare
M&A

Pages